Jacobio Pharmaceuticals Strengthens Shareholding Strategy with Nearly HK$100 Million Investment by Executives
On September 25, 2025, Jacobio Pharmaceuticals (1167.HK) celebrated a remarkable moment in its corporate journey as Dr. Yinxiang Wang, the company's Chairman and CEO, alongside affiliated parties, took a decisive step by increasing their stake in the company by approximately HK$96.34 million. This investment, consisting of 11.06 million shares, underscores their unwavering confidence in the company’s long-term growth potential, setting a robust foundation for a future full of promise.
In conjunction with this share purchase, Jacobio has been executing a strategic repurchase plan approved by its Board in July 2025, initially set with a budget of HK$100 million. So far, the company has successfully repurchased 326,400 shares for a total expenditure of HK$2.67 million, demonstrating its commitment to maximizing shareholder value. Jacobio is poised to continue repurchasing shares depending on market conditions, reflecting a proactive approach to capital management.
Furthermore, Jacobio's interim results for 2025 provide a glimpse into its innovative pursuits and encouraging advancements in research and development. The company is diligently working on two key areas: the KRAS pathway and internal antibody-drug conjugates (iADC). Amongst these, Jacobio's KRAS G12C inhibitor, Glecirasib, has made significant strides. In May 2025, it received approval from the National Medical Products Administration (NMPA) for its use as a second-line monotherapy for non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. Following its launch in China, the successful entry not only represents Jacobio's inaugural venture into the market, but it also activated a milestone payment of RMB 50 million from its collaboration partner, Allist. In parallel, Glecirasib is being evaluated in a novel treatment combination for first-line NSCLC alongside the SHP2 inhibitor sitneprotafib.
Jacobio is not stopping at its marketed products. The company has seen promising advancements with its pan-KRAS inhibitor, JAB-23E73, which has delivered several confirmed partial responses during the ongoing Phase I clinical trial, with safety and pharmacokinetic profiles that align with expectations. Anticipated data from this trial will be released in the first half of 2026, marking a pivotal moment for both Jacobio and the global pan-KRAS market. Additionally, the company is working to advance next-generation KRAS inhibitors, with plans for an IND application for its EGFR-KRAS G12D tADC project slated for submission in late 2026.
In its other R&D area, Jacobio continues to lead in the innovative field of iADC. The company is developing JAB-BX467, a cutting-edge HER2-STING candidate intended to convert traditionally ineffective 'cold tumors' into 'hot tumors,' thus providing new therapeutic options for solid tumors that show limited response to PD-1 monotherapy. At present, this program is at the preclinical stage, with the IND submission also expected in the second half of 2026.
Jacobio’s commitment to driving innovation places it among global leaders in the realms of KRAS and iADC research. The company believes that its current market valuation does not adequately represent the true potential of its promising pipeline or the longevity of its growth trajectory. The recent investment by Dr. Wang and associated parties not only reflects a strong alignment between shareholders and management but also reaffirms their belief in creating long-term value for the company.
In summary, Jacobio Pharmaceuticals is strategically poised for significant future achievement through its innovative focus and notable executive commitment. As the company continues to develop breakthrough treatments for patients worldwide, it aims to solidify its standing in the ever-evolving biopharmaceutical landscape. Interested parties can learn more about Jacobio Pharma and its impressive initiatives at their official website: http://www.jacobiopharma.com.
In conjunction with this share purchase, Jacobio has been executing a strategic repurchase plan approved by its Board in July 2025, initially set with a budget of HK$100 million. So far, the company has successfully repurchased 326,400 shares for a total expenditure of HK$2.67 million, demonstrating its commitment to maximizing shareholder value. Jacobio is poised to continue repurchasing shares depending on market conditions, reflecting a proactive approach to capital management.
Furthermore, Jacobio's interim results for 2025 provide a glimpse into its innovative pursuits and encouraging advancements in research and development. The company is diligently working on two key areas: the KRAS pathway and internal antibody-drug conjugates (iADC). Amongst these, Jacobio's KRAS G12C inhibitor, Glecirasib, has made significant strides. In May 2025, it received approval from the National Medical Products Administration (NMPA) for its use as a second-line monotherapy for non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. Following its launch in China, the successful entry not only represents Jacobio's inaugural venture into the market, but it also activated a milestone payment of RMB 50 million from its collaboration partner, Allist. In parallel, Glecirasib is being evaluated in a novel treatment combination for first-line NSCLC alongside the SHP2 inhibitor sitneprotafib.
Jacobio is not stopping at its marketed products. The company has seen promising advancements with its pan-KRAS inhibitor, JAB-23E73, which has delivered several confirmed partial responses during the ongoing Phase I clinical trial, with safety and pharmacokinetic profiles that align with expectations. Anticipated data from this trial will be released in the first half of 2026, marking a pivotal moment for both Jacobio and the global pan-KRAS market. Additionally, the company is working to advance next-generation KRAS inhibitors, with plans for an IND application for its EGFR-KRAS G12D tADC project slated for submission in late 2026.
In its other R&D area, Jacobio continues to lead in the innovative field of iADC. The company is developing JAB-BX467, a cutting-edge HER2-STING candidate intended to convert traditionally ineffective 'cold tumors' into 'hot tumors,' thus providing new therapeutic options for solid tumors that show limited response to PD-1 monotherapy. At present, this program is at the preclinical stage, with the IND submission also expected in the second half of 2026.
Jacobio’s commitment to driving innovation places it among global leaders in the realms of KRAS and iADC research. The company believes that its current market valuation does not adequately represent the true potential of its promising pipeline or the longevity of its growth trajectory. The recent investment by Dr. Wang and associated parties not only reflects a strong alignment between shareholders and management but also reaffirms their belief in creating long-term value for the company.
In summary, Jacobio Pharmaceuticals is strategically poised for significant future achievement through its innovative focus and notable executive commitment. As the company continues to develop breakthrough treatments for patients worldwide, it aims to solidify its standing in the ever-evolving biopharmaceutical landscape. Interested parties can learn more about Jacobio Pharma and its impressive initiatives at their official website: http://www.jacobiopharma.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.